Company Overview
Snapshot
Founded in August 2008 by Yaniv Dolev and Nava Zisapel, Moebius Medical operates with 1–10 employees. The company has completed one funding round with investors RAD BioMed and Pix Vine Capital, and in September 2024, its lead product MM-II received.
Business overview
Moebius Medical is a clinical-stage biotechnology company focused on developing innovative pain-relief treatments for osteoarthritis. Its core product, MM-II, is a patent-protected intra-articular biolubricant injection designed to reduce pain and prevent joint damage in mild to moderate symptomatic knee osteoarthritis. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals & Diagnostics market, with a focus on patients suffering from inflammatory diseases.
Strategic signal
In September 2024, Moebius Medical's lead product, MM-II, was granted. This designation, announced in collaboration with Sun Pharma, signals a significant acceleration in the development and regulatory review process for MM-II, highlighting its potential to address an unmet medical need and providing a strong validation of the therapy's clinical promise.
Log in to access full profile ›Company Intelligence Q&A
- What is Moebius Medical's primary focus?
- Moebius Medical is a clinical-stage biotechnology company developing novel pain-relief treatments for osteoarthritis, with its lead product, MM-II, targeting symptomatic knee osteoarthritis.
- When was Moebius Medical founded and by whom?
- Moebius Medical was founded in August 2008 by Yaniv Dolev and Nava Zisapel.
- Which investors participated in Moebius Medical's funding round?
- Moebius Medical received funding from investors including Pix Vine Capital.
- What is the latest regulatory milestone for Moebius Medical's MM-II?
- In September 2024, Sun Pharma and Moebius Medical announced that MM-II was granted Fast Track Designation for the treatment of osteoarthritis knee pain.
- What was the outcome of the FDA's review of MM-II in December 2020?
- In December 2020, the FDA cleared Moebius Medical's Investigational New Drug application to initiate a global multi-center phase IIb clinical trial of MM-II for knee osteoarthritis pain.